# XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)

> **NCT01178268** · PHASE4 · COMPLETED · sponsor: **Abbott Medical Devices** · enrollment: 546 (actual)

## Conditions studied

- Coronary Occlusion
- Thrombosis (Stent Thrombosis)
- Vascular Disease
- Myocardial Ischemia
- Coronary Artery Stenosis
- Coronary Disease
- Coronary Artery Disease
- Coronary Restenosis

## Interventions

- **DEVICE:** XIENCE V EECSS
- **DEVICE:** CYPHER SELECT PLUS SECSS

## Key facts

- **NCT ID:** NCT01178268
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-10
- **Final completion:** 2014-09
- **Target enrollment:** 546 (ACTUAL)
- **Last updated:** 2016-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01178268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01178268, "XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01178268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*